Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Prostate biopsy Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Focal Therapy for Localized Prostate Cancer

NCT06270043
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal Therapy
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Sep 23, 2026, 9:24 AM EDT
Completed Phase 1 Interventional

Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer

NCT01359189
View directory record Official record
Conditions
Suspected Primary Prostate Cancer
Interventions
ProxiScan (scintigraphic rectal probe)
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 23, 2026, 9:24 AM EDT
Recruiting Phase 2 Interventional

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

NCT07220720
View directory record Official record
Conditions
Prostate
Interventions
Flotufolastat F 18
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 9:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

NCT02769962
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer, Prostate Cancer
Interventions
EP0057, olaparib, CT scan, CT chest, abdomen, and pelvis, Bone scan, ECG, Echocardiogram, Biopsy
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 23, 2026, 9:24 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

PSMA PET Combined With MRI for the Detection of PCa

NCT07052214
View directory record Official record
Conditions
PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET, Diagnostic Imaging, Elevated PSA, Positron Emission Tomography, Prostate Biopsy, Carcinoma of the Prostate
Interventions
68Ga-PSMA-11
Drug
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 23, 2026, 9:24 AM EDT
Terminated No phase listed Observational

pCHIP: Prostate Cancer Health Impact Program

NCT04293406
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decision Navigation Intervention (DNI)
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Brooklyn, New York • Fresh Meadows, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 23, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT05730712
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Enzalutamide, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 23, 2026, 9:24 AM EDT
Terminated Not applicable Interventional Results available

Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer

NCT02501759
View directory record Official record
Conditions
Health Status Unknown, Prostate Carcinoma
Interventions
3 Tesla Magnetic Resonance Imaging, Gadodiamide, Multiparametric Magnetic Resonance Imaging, Transrectal Biopsy, Ultrasound-Guided Prostate Biopsy
Procedure · Radiation
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 23, 2026, 9:24 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Safety and Efficacy of OTL78 (Zopocianine)

NCT07725523
View directory record Official record
Conditions
Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Interventions
0.06mg/kg ZOPOCIANINE given 1-7 days prior to surgery
Drug
Lead sponsor
Clinton Bahler
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 23, 2026, 9:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

NCT05220501
View directory record Official record
Conditions
Prostate Cancer
Interventions
Microultrasonography Targeted Biopsy, MRI Targeted Biopsy
Diagnostic Test
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older · Male only
Enrollment
804 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Gainsville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 23, 2026, 9:24 AM EDT
Completed Not applicable Interventional

MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer

NCT02303054
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bipolar Radiofrequency Focal Ablation
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 23, 2026, 9:24 AM EDT
Completed No phase listed Observational

Telomere Associated Variables (TAVs) in Prostate Cancer

NCT04124900
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Life Length SL
Industry
Eligibility
18 Years and older · Male only
Enrollment
509 participants
Timeline
2019 – 2023
U.S. locations
2
States / cities
Hialeah, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 23, 2026, 9:24 AM EDT
Recruiting No phase listed Observational

MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer

NCT05241236
View directory record Official record
Conditions
Neoplasms Prostate, Cancer of the Prostate
Interventions
Image Fusion (MR/US) Software Registration Guided Laser Ablation of Prostate Cancer
Device
Lead sponsor
Urological Research Network, LLC
Other
Eligibility
50 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 23, 2026, 9:24 AM EDT
Not listed Not applicable Interventional

ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy

NCT02773940
View directory record Official record
Conditions
Prostate Cancer
Interventions
ClariCore System
Device
Lead sponsor
Precision Biopsy, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 23, 2026, 9:24 AM EDT
Terminated Phase 2 Interventional

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

NCT04754425
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Erdafitinib
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 23, 2026, 9:24 AM EDT
Completed Phase 1 Interventional

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 23, 2026, 9:24 AM EDT
Recruiting No phase listed Observational

EDRN Prostate MRI Biomarker Study

NCT03784924
View directory record Official record
Conditions
PSA, Prostate Cancer
Interventions
MRI prostate
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 23, 2026, 9:24 AM EDT
Terminated Phase 1 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02408861
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 23, 2026, 9:24 AM EDT
Recruiting No phase listed Observational

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

NCT07543757
View directory record Official record
Conditions
Prostate Cancer Detection
Interventions
Proclarix
Diagnostic Test
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
San Diego, California • Meridian, Idaho • Bowling Green, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 23, 2026, 9:24 AM EDT
Completed Not applicable Interventional Results available

PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy

NCT04843566
View directory record Official record
Conditions
Infection
Interventions
Transperineal MRI-guided prostate biopsy, Transrectal MRI-guided prostate biopsy, Antibiotic (prophylaxis)
Procedure · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 23, 2026, 9:24 AM EDT
Withdrawn No phase listed Observational

Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management

NCT01838265
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Transrectal Ultrasound-Guided Biopsy, MRI Ultrasound Biopsy, Expanded Prostate Cancer index Composite Questionnaire, Short-Form 12 of Health Related Quality of Life Questionnaire, Memorial Anxiety Scale for Prostate Cancer, Plasma/Serum Sample for biomarkers, Urine Sample for Biomarkers, Blood Tests for Blood Urea Nitrogen and Creatinine, Blood Test for Serum PSA
Procedure · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 23, 2026, 9:24 AM EDT
Completed Not applicable Interventional Results available

Prostate Cancer Detection Screening MRI Protocol

NCT04175730
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ultrasound and MRI, Ultrasound
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 23, 2026, 9:24 AM EDT
Completed Phase 2 Interventional

Study of Focal Cryoablation in Low-Risk Prostate Cancer

NCT00774436
View directory record Official record
Conditions
Prostate Cancer
Interventions
focal cryotherapy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 23, 2026, 9:24 AM EDT
Completed Not applicable Interventional

Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)

NCT04009083
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care MRI, Fluciclovine PET scan added to MRI
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 23, 2026, 9:24 AM EDT